Heron Therapeutics’ (HRTX) “Buy” Rating Reaffirmed at Noble Financial
Heron Therapeutics (NASDAQ:HRTX)‘s stock had its “buy” rating restated by equities research analysts at Noble Financial in a research note issued on Friday.
HRTX has been the topic of a number of other reports. Mizuho reiterated a “buy” rating and set a $28.00 price objective on shares of Heron Therapeutics in a research note on Tuesday, January 16th. Leerink Swann initiated coverage on shares of Heron Therapeutics in a research note on Tuesday, January 2nd. They set an “outperform” rating and a $22.00 price objective on the stock. ValuEngine upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Cowen reiterated a “buy” rating and set a $40.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, December 6th. Finally, Zacks Investment Research upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $30.08.
Heron Therapeutics (NASDAQ:HRTX) opened at $21.25 on Friday. Heron Therapeutics has a one year low of $12.70 and a one year high of $24.80. The stock has a market cap of $1,190.00, a P/E ratio of -5.61 and a beta of 1.87.
In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the firm’s stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total value of $151,680.00. Following the completion of the sale, the vice president now directly owns 7,584 shares in the company, valued at $151,680. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 19.93% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in HRTX. Perceptive Advisors LLC acquired a new stake in Heron Therapeutics in the third quarter valued at approximately $5,329,000. Rock Springs Capital Management LP acquired a new stake in Heron Therapeutics in the fourth quarter valued at approximately $4,525,000. Vanguard Group Inc. boosted its stake in Heron Therapeutics by 11.8% in the second quarter. Vanguard Group Inc. now owns 2,096,465 shares of the biotechnology company’s stock valued at $29,036,000 after acquiring an additional 221,362 shares in the last quarter. ArrowMark Colorado Holdings LLC boosted its stake in Heron Therapeutics by 33.1% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 838,117 shares of the biotechnology company’s stock valued at $15,170,000 after acquiring an additional 208,548 shares in the last quarter. Finally, Rubric Capital Management LP boosted its stake in Heron Therapeutics by 11.8% in the third quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock valued at $30,685,000 after acquiring an additional 200,000 shares in the last quarter.
TRADEMARK VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/heron-therapeutics-hrtx-buy-rating-reaffirmed-at-noble-financial/1905786.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.